Status:

TERMINATED

Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively

Lead Sponsor:

Hospital Ana Nery

Conditions:

Primary Disease

Eligibility:

All Genders

18-64 years

Phase:

PHASE2

PHASE3

Brief Summary

DAWA is a phase 2, prospective, open-label, randomized, pilot study. The main variable to be observed in this study is intracardiac thrombus. There are no formal primary or secondary clinical efficacy ...

Detailed Description

Mortality and morbidity events (reversible ischemic neurological deficit, ischemic and hemorrhagic stroke, systemic embolism, any bleeding, prosthesis valve thrombosis and death) were evaluated in an ...

Eligibility Criteria

Inclusion

  • Age from 18 to 64 years at entry
  • Patients with mitral and/or aorthic valve bioprosthesis for at least 3 months postoperatively
  • There is 12-lead electrocardiogram documented AF on the day of screening or randomization; or a 24-hour Holter electrocardiogram recording showing AF episodes postoperatively
  • Brain computed tomography scan without hemorrhage or findings of acute cerebral infarction on the last 2 days of screening
  • Exclusion of atrial thrombus or valve prosthesis thrombosis by transesophageal echocardiograph on the last 2 days of screening
  • Written, informed consent

Exclusion

  • Previous hemorrhagic stroke
  • Ischemic stroke in the last 6 months
  • Severe renal impairment (creatinine clearance rates \< 30 ml/min)
  • Active liver disease (any etiology)
  • Concomitant use of any antiplatelet (aspirin, clopidogrel, prasugrel, ticagrelor, ticlopidine, etc)
  • Increased risk of bleeding (congenital or acquired)
  • Uncontrolled hypertension
  • Gastrointestinal hemorrhage within the past year
  • Anemia (hemoglobin level \<10 g/dL) or thrombocytopenia (platelet count \< 100 × 109/L)
  • Active infective endocarditis
  • Pregnant or lactating women

Key Trial Info

Start Date :

August 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2014

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT01868243

Start Date

August 1 2013

End Date

October 1 2014

Last Update

October 9 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Ana Nery

Salvador, Estado de Bahia, Brazil, 40320010

Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively | DecenTrialz